Larvol Veri

BIOMARKER:

LDH-H

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

LDH-H LDH-H	Melanoma Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
LDH-H LDH-H	Melanoma Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
LDH-H LDH-H	Gastric Cancer Gastric Cancer	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3
LDH-H LDH-H	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
LDH-H LDH-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
LDH-H LDH-H	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3